We profiled purified CD19+ B cells from adults with sIgAD without overt clinical symptoms of autoimmunity, to remove any confounding effects of secondary inflammation, and matched controls at baseline and after TLR9 activation. This evidence concerns the gene TLR9 and selective IgA deficiency disease.